SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Moleculin Completes Part A Dosing in Pivotal AML Trial

Moleculin completed dosing of 90 patients in Part A of its Phase 2/3 MIRACLE trial of AnnAraC in relapsed or refractory AML. A comprehensive data readout is expected in Q1 2027 to inform dose selection for Part B.

MBRX

Related stories